Scrip is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
In what appears to be its Series B round, cell therapies developer Rubius Therapeutics Inc. raised $120mm in a highly oversubscribed private financing to 16 investors. The company will use the funds for ongoing development of its Red-Cell Therapeutics, a new class of compounds with potential for treating cancer, autoimmune disease, hemophilia, infectious diseases, and metabolic disorders. Clinical trials should commence in 2018. It will also use some money to expand its team.
Gene Therapy, Cell Therapy
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?